Table 4:
Participant HIV Care Continuum Outcomes by Study Arm and Time Point
| Baseline (N = 130) | 6-Month Follow-Up (n = 116) | 12-Month Follow-Up (n = 117) | 18-Month Follow-Up (n = 117) | Test for Change Over Time w/in Arms | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Immediate Delivery (n = 61) | Delayed Delivery (n = 69) | Immediate Delivery (n = 55) | Delayed Delivery (n = 61) | Immediate Delivery (n = 53) | Delayed Delivery (n = 64) | Immediate Delivery (n = 53) | Delayed Delivery (n = 64) | Immediate Delivery | Delayed Delivery | |
| HIV Care Visit in Past 6 Months | 37 (60.7%) | 44 (63.8%) | 39 (70.9%) | 40 (65.6%) | 32 (60.4%) | 40 (62.5%) | 30 (56.6%) | 40 (62.5%) | ns | ns |
| Currently on ART | 34 (55.7%) | 29 (42.0%) | 38 (69.1%) | 40 (65.6%) | 39 (73.6)% | 47 (73.4%) | 42 (79.3%) | 49 (76.6%) | χ2(3) = 8.13; p = 0.043 | χ2(3) = 21.37; p < 0.001 |
| ART Adherence (Participants on ART only) | (n = 34) | (n = 29) | (n = 38) | (n = 40) | (n = 39) | (n = 47) | (n = 42) | (n = 49) | ||
| Excellent | 1 (2.9%) | 2 (6.9%) | 14 (36.8%) | 12 (30.0%) | 11 (28.2%) | 11 (23.4%) | 18 (42.9%) | 22 (44.9%) | χ2(3) = 16.35; p < 0.001 | χ2(3) = 13.76; p = 0.003 |
| Viral Suppression | ||||||||||
| Self-Reported | 23 (37.7%) | 22 (31.9%) | 32 (58.2%) | 26 (42.6%) | 30 (56.6%) | 27 (42.2%) | 28 (52.8%) | 32 (49.2%) | χ2(3) = 6.19; ns | χ2(3) = 4.27; ns |
| Biomarker-Confirmed | 24 (39.3%) | 27 (39.1%) | 21 (38.2%) | 26 (42.6%) | 23 (43.4%) | 25 (39.1%) | 23 (43.4%) | 26 (40.0%) | χ2(3) = 0.50; ns | χ2(3) = 0.22; ns |
HIV: Human Immunodeficiency Virus: ART: Antiretroviral Therapy; N & n: Sample Size; ns: not significant at p < 0.05; p: probability; χ2: Chi-Square